Pioglitazone improves pelvic ganglion neuronal survival

Cavernosal nerve injury is a common complication after radical prostatectomy and causes erectile dysfunction (ED). Our recent publication established that pioglitazone (PGZ) improves cavernosal nerve function after crush injury in the rat model by both neural protection and neuroregeneration. This result is clinically significant for the many men who undergo treatment for localized prostate cancer. A better understanding of the effects of PGZ on pelvic ganglion neurons after cavernosal nerve injury is warranted. In this Research Highlight, we discuss the implications of our investigation from a molecular and clinical perspective

Hypogonadism, ADAM, and hormone replacement

Male hypogonadism, or testosterone deficiency syndrome (TDS), results from a failure of the testes to produce adequate androgen. Patients have low circulating testosterone in combination with clinical symptoms such as fatigue, erectile dysfunction, and body composition changes. The cause may be primary (genetic anomaly, Klinefelter’s syndrome) or secondary (defect in hypothalamus or pituitary), but often presents with the same symptomatology. In the older patient, androgen deficiency of the aging male (ADAM) is an important cause of secondary hypogonadism because testosterone levels decline progressively after age 40. Hypogonadal patients have alterations not only in sexual function and body composition, but also in cognition and metabolism. Regardless of etiology, hypogonadal patients who are both symptomatic and who have clinically significant alterations in laboratory values are candidates for treatment. The goal of hormone replacement therapy in these men is to restore hormone levels to the normal range and to alleviate symptoms suggestive of hormone deficiency. This can be accomplished in a variety of ways, although most commonly testosterone replacement therapy (TRT) is employed

Hypogonadism, ADAM, and hormone replacement

Abstract: Male hypogonadism, or testosterone deficiency syndrome (TDS), results from a failure of the testes to produce adequate androgen. Patients have low circulating testosterone in combination with clinical symptoms such as fatigue, erectile dysfunction, and body composition changes. The cause may be primary (genetic anomaly, Klinefelter's syndrome) or secondary (defect in hypothalamus or pituitary), but often presents with the same symptomatology. In the older patient, androgen deficiency of the aging male (ADAM) is an important cause of secondary hypogonadism because testosterone levels decline progressively after age 40. Hypogonadal patients have alterations not only in sexual function and body composition, but also in cognition and metabolism. Regardless of etiology, hypogonadal patients who are both symptomatic and who have clinically significant alterations in laboratory values are candidates for treatment. The goal of hormone replacement therapy in these men is to restore hormone levels to the normal range and to alleviate symptoms suggestive of hormone deficiency. This can be accomplished in a variety of ways, although most commonly testosterone replacement therapy (TRT) is employed

H--ED special issue-出版文件-Sp.mdi

a special issue on men's health. We were honored by the invitation to be guest editors for this special issue. We discussed potential topics with many of the contributors while Ms. Qin-Zhu Zheng, Editorial Director of the AJA worked out the details and met with us at the 32nd ASA Annual Meeting in Tampa, Florida. We are very pleased to present this issue of superior articles with contributions by internationally recognized authorities. Andrology is an exciting and vibrant field involving multidisciplinary specialties. Men's health is a relatively new area of interest under the scope of andrology that deals with male reproductive health including male sexual function/ dysfunction, fertility/infertility, male reproductive endocrinology and general well being. In the past two decades our understanding of the physiology of sex has experienced exponential growth. Our knowledge of the pathophysiology of erectile dysfunction (ED) is greater now than at any time before. Each discovery provides new targets for potential therapies and raises new questions. For example, in this issue, researchers from Johns Hopkins describe a novel pathway involving reactive oxygen species (ROS) causing ED through activation of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase It is estimated that 322 million men worldwide will suffer from ED by 2025 Prostate cancer is the leading solid-organ cancer among adult men in the U.S. and radical prostatectomy (RP) is the most common treatment option for clinically localized prostate cancers with excellent long term results. Despite being a first-rate therapy for prostate cancer, RP is associated with several quality of life issues; mainly urinary incontinence (UI) and ED Urethral injury is a very common condition seen in general urologic practice. Surgical reconstruction for urethral stricture disease has now become a mainstay for treatment in refractory cases and the success rate is now well documented throughout the urological community. Surprisingly, despite the magnitude of genital dissection required Men's health is evolving . Editorial